title: Liver transplantation for metastatic neuroendocrine tumors.
abstract: The ideal management of NET must be addressed on a case-by-case basis, with consideration given to patient factors, disease burden, and clinical tumor activity. Outcome improvement for LT in the setting of metastatic disease requires better characterization of the biological behavior of NETs and further identification of factors to be included in the selection criteria. Box 3 summarizes the many areas that have been, and are currently, undergoing investigation. LT as an attempt for cure rather than palliation is a justified treatment option for well-selected patients with metastatic neuroendocrine tumors of the pancreas and GI system. Optimization of pretransplantation staging and patient management algorithms, patient selection, and posttransplant management options are areas that need to be better defined. Further investigations for defining reproducible prognostic factors, consistent histopathologic evaluation, and uniform preoperative staging and site-specific data are needed. With the advancement of newer treatment modalities, it is necessary to define the role of LT along with the optimal perioperative management of existing and recurrent disease.
authors.forename: Haniee
authors.initials: H
authors.lastname: Chung
authors.forename: William C
authors.initials: WC
authors.lastname: Chapman
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D003952:Diagnostic Imaging; D005770:Gastrointestinal Neoplasms / Q000145:classification / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery; D006801:Humans; D015994:Incidence; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery*; D016031:Liver Transplantation; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000145:classification / Q000453:epidemiology / Q000556:secondary* / Q000601:surgery*; D010190:Pancreatic Neoplasms / Q000145:classification / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor